LONDON: GSK plc (LSE/NYSE: GSK) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for the prevention of RSV disease to include adults aged 50-59 at increased risk. Since September 2023, GSK’s RSV vaccine has been…
All posts tagged GSK
GSK acquires full rights to mRNA candidate vaccines
GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations
GSK intends to completely offload Haleon shares
LONDON, UK: GSK plc (LSE/NYSE: GSK) it intends to sell approximately 385 million ordinary shares in Haleon, equivalent to approximately 4.2% of Haleon’s issued share capital and representing GSK’s entire shareholding in Haleon. Following the successful demerger and premium listing of Haleon plc as announced on 18 July 2022, GSK initially retained a 12.94% (Excluding…
GSK completes sale of shares in Haleon
LONDON: GSK plc announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc at a price of 326 pence per share, raising gross proceeds of approximately £978m. Following settlement of the placing, GSK will hold approximately 385m ordinary shares in Haleon, representing approximately 4.2%…
GSK to buy Aiolos Bio for $1.4 billion, boosting its respiratory portfolio
GSK completes acquisition of Aiolos Bio LONDON: GSK plc, a global pharmaceutical company, announced today that it has agreed to acquire Aiolos Bio, Inc., a clinical-stage biotech firm developing a novel antibody therapy for asthma and other inflammatory diseases, for a total of $1.4 billion. The deal will give GSK access to AIO-001, a long-acting…
GSK agrees to acquire Sierra Oncology for $1.9bn
LONDON, UK: GlaxoSmithKline plc (LSE: GSK) and Sierra Oncology Inc (Nasdaq: SRRA) have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity…
GSK announced positive headline results from five studies
LONDON, UK: GlaxoSmithKline plc announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for patients with anaemia due to chronic kidney disease (CKD). The ASCEND programme showed that daprodustat met its primary efficacy endpoint in each study,…
GSK sets new environmental goals
LONDON: GSK has announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030. Increasing scientific evidence demonstrates that climate change and nature loss are impacting the world and human health in many ways, including: extreme heat…
GSK sells its holding in Hindustan Unilever Limited
LONDON: On 1 April 2020 GlaxoSmithKline plc (GSK) announced the completion of its divestment of Horlicks and other Consumer Healthcare nutrition products in India to Unilever, including the merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare Limited (GSK India), and Hindustan Unilever Limited (HUL). Through the merger of GSK India with HUL, GSK acquired…